Symbols

WGS

GeneDx Holdings·NASDAQ

--(--)

WGS fundamentals

WGS Q4 2025 Earnings

GeneDx Holdings (WGS) released its earnings on Feb 23, 2026: revenue was 121.00M (YoY +26.52%), beat estimates; EPS was 0.14 (YoY -81.85%), beat estimates.

Revenue / YoY

121.00M

+26.52%

EPS / YoY

0.14

-81.85%

Report date

Feb 23, 2026

WGS Earnings Call Summary for Q4,2025

Revenue growth acceleration: Q4 2025 exome/genome revenue up 32% YoY, with 27,761 tests (34% YoY growth).
Gross margin expansion: 71% in Q4 2025, up from 45% in 2023, driven by scale and cost optimization.
2026 growth targets: $540M-$555M revenue (33%-35% exome/genome volume growth), 70% gross margin, positive net income.
Strategic initiatives: General pediatrics (50 reps, 1-minute workflow Q3 2026), NICU (10 reps, 60%+ utilization), and international SaaS expansion.
Competitive advantage: Largest rare disease data set (2.5M+ tests), AI-driven diagnostics, and 80%+ market share in rare disease testing.

Earnings

EPS

Revenue

Revenue & Expenses

WGS has released its 2025 Q4 earnings report, with revenue of 120.99M, reflecting a YoY change of 26.50%, and net profit of -17.67M, showing a YoY change of -424.86%. The Sankey diagram below clearly presents WGS's revenue sources and cost distribution.

Key Indicators

GeneDx Holdings (WGS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

GeneDx Holdings (WGS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

GeneDx Holdings (WGS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

GeneDx Holdings (WGS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown